Skip to Main Content

Bluebird Bio is reducing expenses and laying off nearly a third of its employees to preserve cash ahead of two pivotal, gene therapy approval decisions expected later this year, the company said Tuesday.

The restructuring, which aims to save $160 million over the next two years, comes one month after Bluebird warned investors there was “substantial doubt” about its ability to remain solvent beyond this year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment